[Treatment of acute respiratory tract diseases in cattle with Bisolvon in combination with either enrofloxacin, cefquinome, ceftiofur or florfenicol].
The purpose of the present clinical studies was to determine the clinical efficacy of a combined parenteral and oral treatment with Bisolvon in combination with antibiotics in bovines suffering from acute respiratory disease. To this end four trials were conducted in respiratory diseased bovines; a total of 619 animals were evaluated. The animals were randomly assigned to one of two treatment groups within each study and were treated either with enrofloxacin, cefquinome, ceftiofur or florfenicol. The Bisolvon group was additionally treated with Bisolvon over 5 consecutive days. Daily clinical examinations were carried out over a period of 6 days. The clinical respiratory score, the primary parameter, representing a summation of the scoring points for the parameters respiratory rate, nasal discharge, spontaneous coughing, lung sounds and grade of dyspnoea and the clinical index score, which additionally included the general parameters fever, demeanour and feed intake, were significantly lower in the Bisolvon groups compared to the controls at all examinations after initiation of therapy in all trials with the exception of day 2 in one study. Lower values correspond to a less severe clinical condition. This consistent result as well as the evaluation of the single parameters are indicative of an acceleration of the recovery of the animals additionally treated with Bisolvon.
Schmidt
H
H
Boehringer Ingelheim Vetmedica GmbH, Ingelheim/Rhein.
Philipp
H
H
Hamel
U
U
Quirke
J F
JF
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001964:Bromhexine / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D007267:Injections; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000662:veterinary*; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; C053503:ceftiofur; C035534:florfenicol; D013839:Thiamphenicol; D001964:Bromhexine; C068212:cefquinome
Untersuchungen zur Behandlung von akuten Atemwegserkrankungen bei Rindern mit Bisolvon in Kombination mit entweder Enrofloxacin, Cefquinom, Ceftiofur oder Florfenicol.